Literature DB >> 19793590

Therapy adherence issues in Parkinson's disease.

Donald Grosset1.   

Abstract

The response to dopamine replacement therapy in patients with degenerative parkinsonism is variable. Reasons for a poor therapy response include the type of parkinsonism, comorbidities, and differential effects on clinical features. An additional explanation, which has received much less attention, is sub-optimal therapy compliance. Single and multicentre studies of therapy compliance report significant under- and overuse of dopamine replacement therapy resulting in poor symptomatic control, or features of the dopamine dysregulation syndrome or other signs of dopaminergic excess (dyskinesia, confusion, visual hallucinations). In this article, the evidence for sub-optical adherence in Parkinson's disease (PD) is reviewed, and factors associated with sub-optimal compliance were examined, with two case vignettes to illustrate clinical consequences of deviation from the prescribed therapy regimen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19793590     DOI: 10.1016/j.jns.2009.08.053

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

1.  Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study.

Authors:  Giovanni Abbruzzese; Paolo Barone; Roberto Ceravolo; Giovanni Fabbrini; Patrizia Lessi; Alessandra Ori; Lucia Simoni; Michele Tinazzi; Angelo Antonini
Journal:  Neurol Sci       Date:  2015-01-07       Impact factor: 3.307

Review 2.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 3.  Medication adherence in patients with Parkinson's disease.

Authors:  Naveed Malek; Donald G Grosset
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

4.  Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items".

Authors:  G Fabbrini; G Abbruzzese; P Barone; A Antonini; M Tinazzi; G Castegnaro; S Rizzoli; D E Morisky; P Lessi; R Ceravolo
Journal:  Neurol Sci       Date:  2013-06-01       Impact factor: 3.307

5.  Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis.

Authors:  Florent F Richy; Guilhem Pietri; Kimberly A Moran; Emmanuelle Senior; Lydia E Makaroff
Journal:  Appl Health Econ Health Policy       Date:  2013-08       Impact factor: 2.561

6.  Pramipexole and its extended release formulation for Parkinson's disease.

Authors:  Paul S Fishman
Journal:  J Cent Nerv Syst Dis       Date:  2011-06-23

7.  Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Authors:  Bradley J Robottom
Journal:  Patient Prefer Adherence       Date:  2011-01-20       Impact factor: 2.711

8.  The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial.

Authors:  David J Daley; Katherine Ho Deane; Richard J Gray; Paul F Worth; Allan B Clark; Kanagasabesan Sabanathan; Michael Pfeil; Phyo K Myint
Journal:  Trials       Date:  2011-11-28       Impact factor: 2.279

9.  Treatment Responsiveness of Motor Features in Parkinson's Disease: A Matched Case-Control Analysis.

Authors:  Angus D Macleod; Carl E Counsell
Journal:  Mov Disord Clin Pract       Date:  2019-11-21

10.  The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study.

Authors:  Clelia Pellicano; Dario Benincasa; Alessandra Fanciulli; Pamela Latino; Morena Giovannelli; Francesco E Pontieri
Journal:  Eur J Med Res       Date:  2013-12-21       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.